Dr. Jung-Min Ahn
A Trailblazer
Dr. Jung-Min Ahn (South Korea) is a Professor of Interventional Medicine at Asan Medical Center, University of Ulsan College of Medicine. His clinical expertise spans fractional flow reserve (FFR), transcatheter aortic valve replacement (TAVR), and chronic total occlusion (CTO) interventions. He has authored over 500 publications in top peer-reviewed medical journals, including The New England Journal of Medicine (NEJM) and The Lancet. One of his most notable achievements is the landmark BEST trial, which compared the effectiveness of PCI and CABG in patients with multivessel coronary artery disease. Published in the NEJM, the study has been cited over 580 times. He also served as the principal investigator of the ASSURE-DES trial, which evaluated perioperative antiplatelet therapy in patients with drug-eluting stents undergoing non-cardiac surgery. Furthermore, he was the co-principal investigator of the FLASH trial, which demonstrated the noninferiority of Artificial Intelligence (AI)-based automated QCA compared to OCT-guided PCI. He serves as the co-chair of the TCTAP conference.
Dr. Jung-Min Ahn (South Korea) is a Professor of Interventional Medicine at Asan Medical Center, University of Ulsan College of Medicine. His clinical expertise spans fractional flow reserve (FFR), transcatheter aortic valve replacement (TAVR), and chronic total occlusion (CTO) interventions. He has authored over 500 publications in top peer-reviewed medical journals, including The New England Journal of Medicine (NEJM) and The Lancet. One of his most notable achievements is the landmark BEST trial, which compared the effectiveness of PCI and CABG in patients with multivessel coronary artery disease. Published in the NEJM, the study has been cited over 580 times. He also served as the principal investigator of the ASSURE-DES trial, which evaluated perioperative antiplatelet therapy in patients with drug-eluting stents undergoing non-cardiac surgery. Furthermore, he was the co-principal investigator of the FLASH trial, which demonstrated the noninferiority of Artificial Intelligence (AI)-based automated QCA compared to OCT-guided PCI. He serves as the co-chair of the TCTAP conference.